{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:10:19Z","timestamp":1789456219920,"version":"build-2803163510"},"reference-count":40,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) predominantly affects women of reproductive age and carries substantial risks during pregnancy, including disease flare, preeclampsia, acute kidney injury, and adverse fetal outcomes. The therapeutic armamentarium for LN has expanded considerably with the approval of voclosporin, belimumab, and obinutuzumab, yet pregnancy safety data for these agents remain conspicuously absent. Concurrently, the 2024 EULAR recommendations for antirheumatic drugs in reproduction, the 2025 EULAR lupus nephritis update, and the 2024 KDIGO guidelines have reset the landscape of management guidance. This review critically appraises the evidence on the safety and clinical use of all current LN-relevant immunosuppressive and biologic therapies during pregnancy, lactation, and the periconceptional period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive narrative review of literature published between January 2000 and May 2025 was conducted using PubMed, MEDLINE, EMBASE, and Cochrane databases. Key guidelines, pregnancy registries, and landmark clinical trial data were incorporated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management. Tacrolimus is an acceptable calcineurin inhibitor with appropriate therapeutic drug monitoring. Low-dose aspirin is recommended universally to reduce preeclampsia risk. Mycophenolate mofetil is teratogenic and absolutely contraindicated in the first trimester. Voclosporin and obinutuzumab lack any pregnancy safety data and should be avoided. Belimumab data from the pregnancy registry have not raised major signals; selective use may be considered in refractory cases. Rituximab may be used cautiously for life-threatening disease, avoiding the third trimester due to neonatal B-cell depletion. Anifrolumab has no pregnancy data and should be reserved for situations where no compatible alternative exists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The growing number of effective LN therapies creates both opportunities and new dilemmas in pregnancy management. A structured, phase-based approach to drug selection \u2014 anchored in preconception counselling, timely medication switches, and multidisciplinary surveillance \u2014 is essential to optimise maternal and fetal outcomes. Dedicated pregnancy registries for novel biologics are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033261469025","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:06:03Z","timestamp":1783569963000},"page":"1217-1226","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-698X","authenticated-orcid":false,"given":"Sonja","family":"Golubovi\u0107","sequence":"first","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini\u0161a","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Veselinov","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"\u0106eli\u0107","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Popovi\u0107","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Ili\u0107","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"University of Novi Sad"},{"name":"University Clinical Center of Vojvodina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00240110"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2024.1390783"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03309-y"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.007"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.001"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.023"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02279"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101860"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.10.029"},{"issue":"13","key":"e_1_3_3_14_2","first-page":"1364","article-title":"Pregnancy and renal outcomes in lupus nephritis: an update and guide to management","volume":"21","author":"Bramham K","year":"2012","unstructured":"Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus 2012; 21(13): 1364\u20131377. https:\/\/doi.org\/10.1177\/0961203312456893","journal-title":"Lupus"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3270-5"},{"issue":"10","key":"e_1_3_3_16_2","first-page":"e694","article-title":"Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"6","author":"Kroese SJ","year":"2024","unstructured":"Kroese SJ, Abheiden CNH, Blomjous BS, et al. Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis. Lancet Rheumatol 2024; 6(10): e694\u2013e706.","journal-title":"Lancet Rheumatol"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22159"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42793"},{"issue":"11","key":"e_1_3_3_19_2","first-page":"2143","article-title":"Effect of hydroxychloroquine on the risk of recurrent miscarriages in women with rheumatic diseases","volume":"39","author":"Vinet E","year":"2012","unstructured":"Vinet E, Bernatsky S, Hudson M, et al. Effect of hydroxychloroquine on the risk of recurrent miscarriages in women with rheumatic diseases. J Rheumatol 2012; 39(11): 2143\u20132148.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.31083\/j.ceog5110220"},{"issue":"6","key":"e_1_3_3_21_2","first-page":"811","article-title":"Hydroxychloroquine pharmacokinetics and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes","volume":"81","author":"Clowse MEB","year":"2022","unstructured":"Clowse MEB, Eudy AM, Balevic S, et al. Hydroxychloroquine pharmacokinetics and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. Ann Rheum Dis 2022; 81(6): 811\u2013817.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20583"},{"issue":"6","key":"e_1_3_3_23_2","first-page":"946","article-title":"Serious infections in rheumatoid arthritis patients newly treated with azathioprine or hydroxychloroquine","volume":"40","author":"Vinet E","year":"2013","unstructured":"Vinet E, De Moura C, Pineau CA, et al. Serious infections in rheumatoid arthritis patients newly treated with azathioprine or hydroxychloroquine. J Rheumatol 2013; 40(6): 946\u2013951.","journal-title":"J Rheumatol"},{"issue":"3","key":"e_1_3_3_24_2","first-page":"500","article-title":"Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine","volume":"39","author":"Bramham K","year":"2012","unstructured":"Bramham K, Chusney G, Lee J, et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. J Rheumatol 2012; 39(3): 500\u2013504.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200012270-00010"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704559"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000252683.74584.29"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32117"},{"issue":"2","key":"e_1_3_3_30_2","first-page":"e004791","article-title":"Deliberate use of mycophenolate mofetil in pregnant patients with lupus after the first trimester","volume":"11","author":"Vela-Casasempere P","year":"2025","unstructured":"Vela-Casasempere P, Ca\u00f1o Alameda R, G\u00f3mez SS, et al. Deliberate use of mycophenolate mofetil in pregnant patients with lupus after the first trimester. RMD Open 2025; 11(2): e004791.","journal-title":"RMD Open"},{"issue":"6","key":"e_1_3_3_31_2","first-page":"616","article-title":"Pharmacokinetics of cyclophosphamide and its metabolites in pregnant women","volume":"34","author":"Ryu RJ","year":"2014","unstructured":"Ryu RJ, Easterling TR, Caritis SN, et al. Pharmacokinetics of cyclophosphamide and its metabolites in pregnant women. Pharmacotherapy 2014; 34(6): 616\u2013624.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01163.x"},{"issue":"4","key":"e_1_3_3_34_2","first-page":"578","article-title":"Belimumab use during pregnancy: interim results of the belimumab pregnancy registry","volume":"75","author":"Vinet E","year":"2023","unstructured":"Vinet E, Pineau CA, Clarke AE, et al. Belimumab use during pregnancy: interim results of the belimumab pregnancy registry. Arthritis Rheumatol 2023; 75(4): 578\u2013589.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"e_1_3_3_35_2","first-page":"2305","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso Y","year":"2021","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 2021; 73(12): 2305\u20132313. https:\/\/doi.org\/10.1002\/art.41466","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295444"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24130"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf161"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261469025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033261469025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261469025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:34:49Z","timestamp":1789454089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033261469025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/09612033261469025"],"URL":"https:\/\/doi.org\/10.1177\/09612033261469025","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}